



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)  
(AIM: HCM)**

**Chi-Med’s Pharmaceutical R&D Business - Analyst & Investor Briefing**

**London: Wednesday, 9 October 2013:** Chi-Med today announces that further to the announcement made on 3 October 2013 relating to the briefing for investors and analysts to be held at The Brewery (The James Watt room), 52 Chiswell Street, London, EC1Y 4SD today at 9:30 am, it wishes to state that no new material information will be disseminated at the briefing.

**Ends**

**Enquiries**

<b>Chi-Med</b> Christian Hogg, CEO	Telephone: +852 2121 8200
<b>Panmure Gordon (UK) Limited</b> Richard Gray Andrew Potts Grishma Patel	Telephone: +44 20 7886 2500
<b>Citigate Dewe Rogerson</b> Anthony Carlisle David Dible	Telephone: +44 20 7638 9571 Mobile: +44 7973 611 888 Mobile: +44 7967 566 919

**Notes to Editors**

**About HMP**

HMP is a novel drug R&D division focusing on discovering, developing and commercialising innovative therapeutics in oncology and autoimmune diseases. With a team of around 200 scientists and staff, its pipeline is comprised of novel oral compounds for cancer and inflammation in development in North America, Europe, Australia and Greater China.

HMP is majority owned by Chi-Med. For more information, please visit: [www.hmpglobal.com](http://www.hmpglobal.com).

## **About Chi-Med**

Chi-Med is the holding company of a healthcare group based primarily in China and was listed on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing and selling pharmaceuticals and health oriented consumer products.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited. For more information, please visit: [www.chi-med.com](http://www.chi-med.com).